Describe updated who classification of lung tumors along with detailed morphology , IHC and molecular genetics from references like robbins and ackerman

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Searching Images

lung adenocarcinoma lepidic pattern histology

This is a histopathology slide of lung tissue prepared for light microscopy, stained with Hematoxylin and Eosin (H&E). The sample demonstrates a lepidic adenocarcinoma pattern, with neoplastic columnar epithelial cells proliferating along preexisting alveolar walls (lepidic growth) and partially preserving alveolar architecture. In the lower half of the field, neoplastic cells line and expand the alveolar septa, producing subtle crowding of nuclei with mild to moderate atypia and low mitotic activity. There is no conspicuous desmoplasia or stromal invasion evident in this view, although invasion may be focal and better assessed on additional sections. Some tumor cells show intracellular mucin. The background lung parenchyma displays relatively preserved air spaces and occasional inflammatory cells. The overall histology is compatible with lung adenocarcinoma, lepidic predominant or adenocarcinoma in situ spectrum, and could represent early invasive adenocarcinoma depending on invasion assessment in deeper sections. Clinically, lepidic growth pattern carries relatively favorable prognosis compared with other invasive adenocarcinoma subtypes when invasion is limited. This image is suitable for educational illustration of pulmonary adenocarcinoma subtypes, differential diagnosis with atypical adenomatous hyperplasia and adenocarcinoma in situ, and correlation with radiologic ground-glass opacities. Further sections may reveal invasive components not seen here. Correlation with radiologic imaging can aid staging.

This is a histopathology slide of lung tissue prepared for light microscopy, stained with Hematoxylin and Eosin (H&E). The sample demonstrates a lepidic adenocarcinoma pattern, with neoplastic columnar epithelial cells proliferating along preexisting alveolar walls (lepidic growth) and partially preserving alveolar architecture. In the lower half of the field, neoplastic cells line and expand the alveolar septa, producing subtle crowding of nuclei with mild to moderate atypia and low mitotic activity. There is no conspicuous desmoplasia or stromal invasion evident in this view, although invasion may be focal and better assessed on additional sections. Some tumor cells show intracellular mucin. The background lung parenchyma displays relatively preserved air spaces and occasional inflammatory cells. The overall histology is compatible with lung adenocarcinoma, lepidic predominant or adenocarcinoma in situ spectrum, and could represent early invasive adenocarcinoma depending on invasion assessment in deeper sections. Clinically, lepidic growth pattern carries relatively favorable prognosis compared with other invasive adenocarcinoma subtypes when invasion is limited. This image is suitable for educational illustration of pulmonary adenocarcinoma subtypes, differential diagnosis with atypical adenomatous hyperplasia and adenocarcinoma in situ, and correlation with radiologic ground-glass opacities. Further sections may reveal invasive components not seen here. Correlation with radiologic imaging can aid staging.

This image depicts a hematoxylin and eosin stained histology slide of lung parenchyma showing invasive non-mucinous adenocarcinoma with a lepidic growth pattern. The neoplastic epithelium lines and expands the alveolar septa with columnar to cuboidal atypical pneumocytes resembling type II pneumocytes or Clara cells. Lepidic spread is evident as neoplastic cells proliferate along preexisting alveolar walls, often preserving underlying architecture. In this specimen, components typical of lepidic growth may co-occur with minor areas showing acinar, papillary, micropapillary or solid differentiation, illustrating the histologic continuum described in contemporary classification. The lepidic areas frequently lack fibrovascular cores, contrasting with true papillary architecture; mucin production is not prominent in the shown fields. The tumor demonstrates nuclear atypia, mitotic activity may be inconspicuous, and alveolar spaces remain partly preserved by tumoral lining, contributing to a morphological impression of invasive lepidic adenocarcinoma. Correct classification requires semi-quantitative assessment of the lepidic component versus invasive patterns, as per the WHO 2015 guidelines, since prognosis and therapeutic implications depend on predominant histology. This image is relevant for pathology education, differential diagnosis discussions, and correlation with radiologic ground-glass opacities. The image serves as a reference for grading lepidic dominance and for correlating histology with radiographic patterns in thoracic oncology education and research.

This image depicts a hematoxylin and eosin stained histology slide of lung parenchyma showing invasive non-mucinous adenocarcinoma with a lepidic growth pattern. The neoplastic epithelium lines and expands the alveolar septa with columnar to cuboidal atypical pneumocytes resembling type II pneumocytes or Clara cells. Lepidic spread is evident as neoplastic cells proliferate along preexisting alveolar walls, often preserving underlying architecture. In this specimen, components typical of lepidic growth may co-occur with minor areas showing acinar, papillary, micropapillary or solid differentiation, illustrating the histologic continuum described in contemporary classification. The lepidic areas frequently lack fibrovascular cores, contrasting with true papillary architecture; mucin production is not prominent in the shown fields. The tumor demonstrates nuclear atypia, mitotic activity may be inconspicuous, and alveolar spaces remain partly preserved by tumoral lining, contributing to a morphological impression of invasive lepidic adenocarcinoma. Correct classification requires semi-quantitative assessment of the lepidic component versus invasive patterns, as per the WHO 2015 guidelines, since prognosis and therapeutic implications depend on predominant histology. This image is relevant for pathology education, differential diagnosis discussions, and correlation with radiologic ground-glass opacities. The image serves as a reference for grading lepidic dominance and for correlating histology with radiographic patterns in thoracic oncology education and research.

Histopathology image depicts primary non-mucinous lung adenocarcinoma with a lepidic growth pattern. Hematoxylin and eosin stained sections show cuboidal to low-columnar malignant cells lining alveolar septa and projecting into alveolar spaces, creating a characteristic lepidic architecture with preservation of alveolar outlines and minimal desmoplasia. Scattered anthracotic pigment granules are present within the alveolar septa and spaces. The inset immunohistochemical panel demonstrates strong nuclear positivity for TTF-1 in tumor cells, supporting a pulmonary origin and helping differentiate from metastatic carcinomas that are typically TTF-1 negative (with exceptions such as some thyroid metastases). The described immunoprofile of primary lung adenocarcinoma commonly includes CK7+, TTF-1+, Napsin A+, EMA+, CEA+, with CK20-, CDX2-, MUC2- in many cases, though CDX2 can be positive in mucinous variants. Overall, the image emphasizes non-mucinous histology, lepidic polarity, and the diagnostic value of TTF-1 staining for establishing a primary lung adenocarcinoma versus metastasis. Clinically relevant for diagnosis, prognosis assessment, and guiding molecular testing and therapeutic planning.

Histopathology image depicts primary non-mucinous lung adenocarcinoma with a lepidic growth pattern. Hematoxylin and eosin stained sections show cuboidal to low-columnar malignant cells lining alveolar septa and projecting into alveolar spaces, creating a characteristic lepidic architecture with preservation of alveolar outlines and minimal desmoplasia. Scattered anthracotic pigment granules are present within the alveolar septa and spaces. The inset immunohistochemical panel demonstrates strong nuclear positivity for TTF-1 in tumor cells, supporting a pulmonary origin and helping differentiate from metastatic carcinomas that are typically TTF-1 negative (with exceptions such as some thyroid metastases). The described immunoprofile of primary lung adenocarcinoma commonly includes CK7+, TTF-1+, Napsin A+, EMA+, CEA+, with CK20-, CDX2-, MUC2- in many cases, though CDX2 can be positive in mucinous variants. Overall, the image emphasizes non-mucinous histology, lepidic polarity, and the diagnostic value of TTF-1 staining for establishing a primary lung adenocarcinoma versus metastasis. Clinically relevant for diagnosis, prognosis assessment, and guiding molecular testing and therapeutic planning.

Searching Images

small cell lung carcinoma histology microscopy

Imaging modality: Light microscopy of hematoxylin and eosin (H&E) stained lung tissue section. Primary subject: small cell lung carcinoma (SCLC) tumor cells derived from bronchogenic carcinoma. Specimen: bronchial/lung parenchyma biopsy; histologic section prepared from paraffin-embedded tissue, typically 4-5 micrometers thick. Imaging perspective: high-magnification cellular view under brightfield illumination. Visual features: the tumor shows dense sheets and clusters of small, round to oval cells with scant cytoplasm and ill-defined cytoplasmic borders, producing a densely packed, blue-gray appearance on H&E. Nuclei are hyperchromatic with finely dispersed granular chromatin giving a salt-and-pepper pattern; nucleoli are absent or inconspicuous. Nuclear molding is a constant finding. Mitotic activity is markedly increased, with numerous mitotic figures; necrosis is commonly present within tumor nests. The morphology is that of a high-grade neuroendocrine carcinoma, with little cytoplasm and abrupt cell borders. Background tissue often contains necrotic debris and crush artifacts near tumor clusters. This histology supports differentiation from non-small cell lung carcinomas, in which chromatin may be coarser and nucleoli more conspicuous. Clinically, SCLC is aggressive with early metastatic potential and a distinct therapeutic approach; histology guides diagnosis, prognosis, staging, and treatment planning, including chemotherapy and radiotherapy regimens and consideration of paraneoplastic syndromes.

Imaging modality: Light microscopy of hematoxylin and eosin (H&E) stained lung tissue section. Primary subject: small cell lung carcinoma (SCLC) tumor cells derived from bronchogenic carcinoma. Specimen: bronchial/lung parenchyma biopsy; histologic section prepared from paraffin-embedded tissue, typically 4-5 micrometers thick. Imaging perspective: high-magnification cellular view under brightfield illumination. Visual features: the tumor shows dense sheets and clusters of small, round to oval cells with scant cytoplasm and ill-defined cytoplasmic borders, producing a densely packed, blue-gray appearance on H&E. Nuclei are hyperchromatic with finely dispersed granular chromatin giving a salt-and-pepper pattern; nucleoli are absent or inconspicuous. Nuclear molding is a constant finding. Mitotic activity is markedly increased, with numerous mitotic figures; necrosis is commonly present within tumor nests. The morphology is that of a high-grade neuroendocrine carcinoma, with little cytoplasm and abrupt cell borders. Background tissue often contains necrotic debris and crush artifacts near tumor clusters. This histology supports differentiation from non-small cell lung carcinomas, in which chromatin may be coarser and nucleoli more conspicuous. Clinically, SCLC is aggressive with early metastatic potential and a distinct therapeutic approach; histology guides diagnosis, prognosis, staging, and treatment planning, including chemotherapy and radiotherapy regimens and consideration of paraneoplastic syndromes.

Imaging modality: light microscopy of hematoxylin and eosin (H&E) stained lung tissue biopsy; specimen: lung parenchyma, central airways, consistent with small cell lung carcinoma (SCLC). The histology shows sheets and clusters of very small round to oval cells with scant cytoplasm and ill-defined borders, resulting in a high nuclear-to-cytoplasmic ratio. Nuclei are hyperchromatic with finely dispersed granular chromatin described as salt-and-pepper, and nucleoli are absent or inconspicuous. Nuclear molding is a constant and defining feature, with intimate contiguity of nuclei that distorts cell borders. Mitotic activity is brisk and necrosis is commonly present, reflecting the high-grade nature of SCLC, which by definition is high-grade and lacks a conventional grading scale. The tumor often displays crush artifact and necrotic debris in intercellular spaces. The morphology helps distinguish SCLC from non-small cell carcinoma, where chromatin tends to be clumpy and nucleoli are more conspicuous. Immunohistochemistry may further support diagnosis, with neuroendocrine markers such as synaptophysin, chromogranin A, and CD56 typically positive, and TTF-1 often variably expressed. Clinically, these findings correlate with aggressive behavior, early metastatic potential, and a treatment paradigm dominated by systemic chemotherapy and radiotherapy. The image is essential for education and reference in pathology, oncology, and thoracic medicine. Educational reference material.

Imaging modality: light microscopy of hematoxylin and eosin (H&E) stained lung tissue biopsy; specimen: lung parenchyma, central airways, consistent with small cell lung carcinoma (SCLC). The histology shows sheets and clusters of very small round to oval cells with scant cytoplasm and ill-defined borders, resulting in a high nuclear-to-cytoplasmic ratio. Nuclei are hyperchromatic with finely dispersed granular chromatin described as salt-and-pepper, and nucleoli are absent or inconspicuous. Nuclear molding is a constant and defining feature, with intimate contiguity of nuclei that distorts cell borders. Mitotic activity is brisk and necrosis is commonly present, reflecting the high-grade nature of SCLC, which by definition is high-grade and lacks a conventional grading scale. The tumor often displays crush artifact and necrotic debris in intercellular spaces. The morphology helps distinguish SCLC from non-small cell carcinoma, where chromatin tends to be clumpy and nucleoli are more conspicuous. Immunohistochemistry may further support diagnosis, with neuroendocrine markers such as synaptophysin, chromogranin A, and CD56 typically positive, and TTF-1 often variably expressed. Clinically, these findings correlate with aggressive behavior, early metastatic potential, and a treatment paradigm dominated by systemic chemotherapy and radiotherapy. The image is essential for education and reference in pathology, oncology, and thoracic medicine. Educational reference material.

Imaging modality and technique: Brightfield light microscopy of a hematoxylin and eosin–stained lung biopsy section. Primary subject: small cell carcinoma of the lung (SCLC), a high‑grade neuroendocrine carcinoma commonly arising centrally in smokers. Specimen: bronchoscopic or percutaneous core biopsy tissue displaying dense cellularity within lung parenchyma. Morphologic features: numerous small, round to oval cells with scant cytoplasm and ill‑defined borders, forming sheets and clusters. Nuclear characteristic: hyperchromatic, finely dispersed salt‑and‑pepper chromatin with absent or inconspicuous nucleoli and pronounced nuclear molding. Cytoplasm is tenuous, giving a characteristic high nuclear‑to‑cytoplasmic ratio. Mitotic activity is brisk with frequent atypical mitoses; extensive necrosis is often present, contributing to geographic tumor necrosis on histology. Background stroma is usually fibrotic or desmoplastic, and crush artifacts may accentuate nuclear crowding. These features collectively define a high‑grade phenotype with aggressive biology. Diagnostic significance: when present, these findings support SCLC diagnosis and guide rapid systemic chemotherapy and radiotherapy planning. Context and differential: morphological distinction from non‑small cell lung carcinoma relies on chromatin pattern (finely dispersed, no clumps) and nucleoli, rather than nuclear size or neuroendocrine differentiation. Correlation with immunohistochemistry (e.g., synaptophysin, chromogranin A) reinforces the diagnosis and informs prognosis and treatment planning.

Imaging modality and technique: Brightfield light microscopy of a hematoxylin and eosin–stained lung biopsy section. Primary subject: small cell carcinoma of the lung (SCLC), a high‑grade neuroendocrine carcinoma commonly arising centrally in smokers. Specimen: bronchoscopic or percutaneous core biopsy tissue displaying dense cellularity within lung parenchyma. Morphologic features: numerous small, round to oval cells with scant cytoplasm and ill‑defined borders, forming sheets and clusters. Nuclear characteristic: hyperchromatic, finely dispersed salt‑and‑pepper chromatin with absent or inconspicuous nucleoli and pronounced nuclear molding. Cytoplasm is tenuous, giving a characteristic high nuclear‑to‑cytoplasmic ratio. Mitotic activity is brisk with frequent atypical mitoses; extensive necrosis is often present, contributing to geographic tumor necrosis on histology. Background stroma is usually fibrotic or desmoplastic, and crush artifacts may accentuate nuclear crowding. These features collectively define a high‑grade phenotype with aggressive biology. Diagnostic significance: when present, these findings support SCLC diagnosis and guide rapid systemic chemotherapy and radiotherapy planning. Context and differential: morphological distinction from non‑small cell lung carcinoma relies on chromatin pattern (finely dispersed, no clumps) and nucleoli, rather than nuclear size or neuroendocrine differentiation. Correlation with immunohistochemistry (e.g., synaptophysin, chromogranin A) reinforces the diagnosis and informs prognosis and treatment planning.

I now have comprehensive material. Let me compile the full detailed response:

WHO 2021 Classification of Lung Tumors: Morphology, IHC, and Molecular Genetics

(Based on Robbins & Kumar Basic Pathology, Fishman's Pulmonary Diseases and Disorders, Sabiston Textbook of Surgery, and Harrison's Principles of Internal Medicine)

Overview and Historical Context

The WHO has classified lung tumors through four major editions (1999, 2004, 2015, 2021). The 2021 WHO classification represents the most significant update, driven by three forces:
  1. Widespread adoption of targeted therapies requiring precise molecular subtyping
  2. Recognition that most patients present with advanced disease and small biopsy/cytology specimens
  3. Improved immunohistochemical profiling and genomic characterization
The 2021 edition specifically expands commentary on small diagnostic samples, modernizes IHC-based subtype classification, and broadens the emphasis on genetic testing. - Sabiston Textbook of Surgery
Approximately 95% of primary lung tumors are carcinomas; the remaining 5% include carcinoids, mesenchymal malignancies, lymphomas, and rare benign lesions such as pulmonary hamartoma. - Robbins & Kumar Basic Pathology

WHO 2021 Major Categories of Malignant Lung Tumors

CategoryKey Subtypes
AdenocarcinomaAIS, MIA, Invasive (lepidic, acinar, papillary, micropapillary, solid, invasive mucinous)
Squamous Cell CarcinomaKeratinizing, Non-keratinizing, Basaloid
Large Cell CarcinomaUndifferentiated (diagnosis of exclusion)
Adenosquamous CarcinomaMixed SCC + adenocarcinoma (>10% each)
Sarcomatoid CarcinomaPleomorphic, Spindle cell, Giant cell, Carcinosarcoma, Pulmonary blastoma
Neuroendocrine TumorsTypical carcinoid, Atypical carcinoid, LCNEC, Small cell carcinoma
Salivary Gland-type TumorsMucoepidermoid, Adenoid cystic

1. Adenocarcinoma

Epidemiology and Background
Adenocarcinoma is now the most common histologic subtype of lung carcinoma worldwide, accounting for approximately 50% of all lung cancers. It is the predominant subtype in:
  • Women
  • Never-smokers
  • Patients under 45 years old
  • People of Asian descent
It tends to metastasize earlier than squamous cell carcinoma, with a predilection for CNS involvement. Most tumors (75%) are peripherally located. - Sabiston Textbook of Surgery
Precursor Lesions
The 2021 WHO classification recognizes a clear stepwise progression:
  • Atypical Adenomatous Hyperplasia (AAH): Cuboidal epithelium with mild nuclear atypia and mild interstitial fibrosis. Lesion <5 mm. The earliest recognized precursor.
  • Adenocarcinoma in Situ (AIS): ≤3 cm solitary lesion with pure lepidic growth (tumor cells growing along alveolar septa without invasion, stromal, vascular, or pleural involvement). Replaced the old term "bronchioloalveolar carcinoma" (BAC). Typically nonmucinous. 100% disease-free survival after complete resection.
  • Minimally Invasive Adenocarcinoma (MIA): ≤3 cm solitary lesion with predominantly lepidic growth and invasion ≤0.5 cm. Near 100% disease-free survival after resection.
The critical historic revision: the 2015 WHO classification abolished the term BAC entirely, replacing it with AIS and MIA. This was validated by studies showing that even small foci of invasion >5 mm altered prognosis. - Fishman's Pulmonary Diseases and Disorders
Morphology - Invasive Adenocarcinoma
The 2021 WHO classification defines five major growth patterns for invasive non-mucinous adenocarcinoma, classified by predominant pattern:
  1. Lepidic predominant: Tumor cells proliferate along preexisting alveolar walls without destruction. Cuboidal to columnar cells resembling type II pneumocytes. Best prognosis among invasive subtypes.
  2. Acinar predominant: Gland-forming, round to oval spaces lined by cuboidal to columnar cells. Intermediate prognosis.
  3. Papillary predominant: Tumor cells lining true fibrovascular cores.
  4. Micropapillary predominant: Small papillary tufts lacking fibrovascular cores, floating in alveolar spaces. Associated with worst prognosis among adenocarcinoma subtypes and high rate of lymphovascular invasion.
  5. Solid predominant: Sheets of polygonal cells with abundant cytoplasm, without acinar, papillary, or lepidic formation, but with intracytoplasmic mucin on special stains.
Special subtypes include:
  • Invasive Mucinous Adenocarcinoma (formerly mucinous BAC): Tall columnar goblet cells with basal nuclei and abundant apical mucin, growing in lepidic or acinar pattern. Often multifocal or lobar pneumonic pattern. Associated with KRAS mutations.
  • Colloid adenocarcinoma, Fetal adenocarcinoma, Enteric-type adenocarcinoma: Rarer subtypes.
IHC Profile
MarkerStatus
TTF-1 (Thyroid Transcription Factor-1)Positive (~75-85% of adenocarcinomas)
Napsin APositive (highly specific for lung adenocarcinoma)
CK7Positive
CK20Negative
CDX2Negative (positive in enteric and mucinous variants)
CEAPositive
p40, p63Negative
Synaptophysin, ChromograninNegative
TTF-1 and Napsin A together are the most useful panel to confirm lung adenocarcinoma origin. Mucinous adenocarcinomas may be TTF-1 negative but CK7 positive.
Molecular Genetics
Adenocarcinoma has the richest landscape of targetable driver mutations:
Mutation/AlterationFrequencyNotes
KRAS~30% (mostly smokers)Most common in Western populations; oncogenic RAS signaling; mucinous subtype
EGFR~20% overall; up to 50% in Asian/never-smoker womenExon 19 deletions, Exon 21 L858R point mutation; most common in nonsmokers/women/Asians
ALK rearrangement4-6%Fusion with EML4 or other partners; often signet ring morphology; exclusive with EGFR/KRAS
ROS1 rearrangement1-2%Shares features with ALK+ tumors; young nonsmokers
BRAF V600E~2%Small subset amenable to targeted therapy
MET exon 14 skipping~3%Associated with older patients
RET rearrangement~1-2%Targetable with RET inhibitors
NTRK fusionRarePan-tumor target
STK11 (LKB1)~15-30%Co-occurs with KRAS; associated with immunotherapy resistance
TP53~50%Loss of function
3p deletions~80%Includes VHL, FHIT loci
  • Robbins & Kumar Basic Pathology, Table 11.6
EGFR and ALK mutations are mutually exclusive. EGFR mutations respond remarkably to tyrosine kinase inhibitors (gefitinib, erlotinib, osimertinib), but resistance typically develops within months to a year, often through secondary EGFR mutations (T790M) or bypass signaling. - Robbins
Lung adenocarcinoma, lepidic pattern - H&E
Lung adenocarcinoma, lepidic pattern: neoplastic columnar cells proliferating along preexisting alveolar walls without stromal invasion

2. Squamous Cell Carcinoma (SCC)

Epidemiology
SCC accounts for approximately 30% of all lung cancers. Over 90% occur in cigarette smokers. Two-thirds are centrally located (arising from main/lobar/segmental bronchi). SCC tends to metastasize later than adenocarcinoma and may be more detectable on sputum cytology. - Sabiston Textbook of Surgery
Precursor Lesions
The stepwise progression is best documented in SCC:
  • Squamous metaplasia → squamous dysplasia (mild, moderate, severe) → squamous carcinoma in situ → invasive SCC
  • An in-situ component in a resected specimen helps confirm primary pulmonary origin vs. metastasis from head and neck. - Fishman's Pulmonary Diseases
Morphology
  • Gross: Central endobronchial mass, often with post-obstructive collapse/pneumonitis distal to tumor. Prone to central necrosis and cavitation.
  • Microscopic hallmarks: keratinization (keratin pearls), intercellular bridges (desmosomes between cells), stratification.
  • Well-differentiated SCC: abundant keratin pearls, easily visible intercellular bridges.
  • Moderately differentiated: less keratinization.
  • Poorly differentiated: sheets of cells without clear squamous features - requires IHC.
  • Basaloid subtype: nests of small cells with peripheral palisading and minimal keratinization; must be distinguished from LCNEC.
  • Desmoplastic stroma with nests of infiltrating squamous cell carcinoma is characteristic.
IHC Profile
MarkerStatus
p40 (best) / p63Strongly positive (most specific)
CK5/6Positive
SOX2Positive
Desmoglein-3Positive
TTF-1Negative
Napsin ANegative
CK7Negative or focal
p40 is the single most specific marker, preferred over p63 (which can be expressed in small numbers of adenocarcinomas).
Molecular Genetics
SCC has a distinct genomic profile from adenocarcinoma:
AlterationFrequency
TP53~80%
CDKN2A (p16) deletion/mutation~50%
SOX2 amplification~30%
FGFR1 amplification~20%
PIK3CA~15%
DDR2 mutation~10%
PTEN loss~10-15%
3p deletions~80%
RB mutations~20%
KRASRare
EGFRRare (in Western patients)
ALKAbsent
SCC is not typically driven by the actionable kinase mutations that define adenocarcinoma therapeutics. It does express parathyroid hormone-related peptide (PTHrP), responsible for hypercalcemia as a paraneoplastic syndrome. - Robbins Table 11.6

3. Small Cell Lung Carcinoma (SCLC)

Epidemiology
SCLC accounts for approximately 15-20% of all lung cancers. It is overwhelmingly associated with heavy smoking (95%). About 80% are centrally located. SCLC is virtually always metastatic at presentation, making surgical resection rarely curative. - Sabiston Textbook of Surgery
Morphology
SCLC is defined by high-grade neuroendocrine morphology:
  • Gross: Soft, white-gray central mass, often with extensive mediastinal/hilar lymph node involvement. Necrosis prominent.
  • Microscopic:
    • Small round to oval cells, scant cytoplasm, ill-defined borders
    • High nuclear-to-cytoplasmic ratio
    • Finely dispersed granular ("salt-and-pepper") chromatin
    • Absent or inconspicuous nucleoli
    • Nuclear molding (adjacent nuclei deform each other) - characteristic
    • Diffuse sheets or clusters; organoid nesting pattern absent (unlike carcinoid)
    • Brisk mitotic activity (>10/2 mm², typically very high)
    • Extensive necrosis common
    • Crush artifact is frequent in small biopsies
    • Dense-core neurosecretory granules on electron microscopy
Small cell lung carcinoma H&E
Small cell lung carcinoma: dense sheets of small cells with scant cytoplasm, salt-and-pepper chromatin, nuclear molding, and brisk mitoses
IHC Profile
MarkerStatus
SynaptophysinPositive
Chromogranin APositive (can be focal/weak)
CD56 (NCAM)Strongly positive
TTF-1Positive (~80-90%)
CK (low molecular weight, dot-like/paranuclear pattern)Positive
p40, p63Negative
Ki-67>80% (often >90%)
PD-L1Variable
Epithelial markers (EMA, CEA, cytokeratin) are present in both SCLC and NSCLC. The key discriminator is neuroendocrine marker expression AND TTF-1 with p40 negativity. - Robbins Table 11.6
Molecular Genetics
SCLC has a unique, highly altered genomic profile:
AlterationFrequency
TP53 mutation~90%
RB1 mutation/deletion~90% (near universal)
3p deletions~90%
MYCL1 amplification~30%
MYCN amplification~5-10%
MYC amplification~5-10%
CREBBP/EP300~15%
NOTCH family~25%
SOX2 amplificationPresent
KRASRare
EGFRAbsent
ALKAbsent
The near-universal RB1 + TP53 loss is the defining molecular signature of SCLC - equivalent to complete inactivation of the two founding tumor suppressor pathways. SCLC has one of the highest mutation burdens of any cancer (due to tobacco carcinogens) yet is paradoxically unresponsive to immune checkpoint inhibitors in most cases. - Robbins Table 11.6
SCLC is associated with production of peptide hormones as paraneoplastic phenomena: ACTH (ectopic Cushing syndrome), ADH (SIADH), gastrin-releasing peptide (GRP), and calcitonin.

4. Large Cell Neuroendocrine Carcinoma (LCNEC)

LCNEC represents a high-grade neuroendocrine carcinoma of the lung with "large cell" (NSCLC-like) morphology:
Morphology:
  • Organoid, trabecular, rosette-like, or palisading architecture
  • Large cells with moderate-to-abundant cytoplasm (contrast with SCLC)
  • Prominent nucleoli
  • High mitotic rate (>10/2 mm², typically much higher)
  • Widespread necrosis
  • Neuroendocrine differentiation confirmed by IHC
IHC: Synaptophysin, chromogranin, CD56 positive. TTF-1 variably positive. p40 negative. Ki-67 >50%.
Molecular genetics: LCNEC can be divided into "SCLC-like" (TP53+RB1) and "NSCLC-like" (TP53+STK11 or KEAP1) subtypes, with therapeutic implications. - Fishman's Pulmonary Diseases

5. Typical and Atypical Carcinoid

Overview: Carcinoid tumors account for <2% of all lung cancers. The 2021 WHO recognizes two subtypes based on histologic grade:
FeatureTypical Carcinoid (TC)Atypical Carcinoid (AC)
Mitoses<2/2 mm²2-10/2 mm²
NecrosisAbsentPresent (punctate/focal)
5-yr survival~90%~70%
LN metastases~5-10%~30%
Morphology:
  • Organoid, trabecular, rosette, palisading, or spindle cell patterns
  • Uniform cells with moderate granular eosinophilic cytoplasm
  • Round to oval nuclei with finely stippled ("salt-and-pepper") chromatin
  • Absent or inconspicuous nucleoli
  • Vascular stroma
IHC: Synaptophysin, chromogranin A, CD56 strongly positive. TTF-1 variable. Ki-67: TC < 5%, AC 5-20%.
Molecular genetics: Carcinoids are genetically distinct from high-grade neuroendocrine carcinomas. They have low mutation burden, with recurrent mutations in MEN1, PSIP1, ARID1A, and chromatin remodeling genes. EGFR, KRAS, and TP53 mutations are uncommon. - Fishman's Pulmonary Diseases

6. Large Cell Carcinoma

With widespread use of IHC and molecular profiling, large cell carcinoma (LCC) has been dramatically reclassified, dropping from ~10% to only ~1.5% of all lung cancers. The 2021 WHO defines LCC as a strict diagnosis of exclusion:
"An undifferentiated non-small-cell carcinoma that lacks the cytologic, architectural, and immunohistochemical features of SCLC, adenocarcinoma, or squamous cell carcinoma, AND lacks giant cell, spindle cell, or pleomorphic features."
Morphology:
  • Large sheets of round to polygonal cells
  • Prominent nucleoli
  • Abundant pale-staining cytoplasm
  • No glandular, squamous, or neuroendocrine differentiation
  • No mucin production
  • Usually large and peripherally located
IHC: All lineage markers (TTF-1, Napsin A, p40, p63, synaptophysin, chromogranin) are negative by definition.
Molecular genetics: No specific genomic driver; heterogeneous. Some cases harbor KRAS or TP53 mutations.

7. Sarcomatoid Carcinoma

A group of poorly differentiated NSCLCs with sarcoma-like features. Five subtypes recognized by WHO:
  1. Pleomorphic carcinoma: Contains >10% spindle and/or giant cells, or is exclusively composed of them, WITH an adenocarcinoma/SCC component.
  2. Spindle cell carcinoma: Purely spindle cells
  3. Giant cell carcinoma: Purely giant cells with inflammatory infiltrate (hallmark: neutrophilic emperipolesis)
  4. Carcinosarcoma: True biphasic tumor with malignant epithelial and heterologous sarcomatous components (rhabdomyosarcoma, chondrosarcoma, osteosarcoma)
  5. Pulmonary blastoma: Resembles embryonic lung; biphasic fetal adenocarcinoma + sarcomatous stroma
IHC: AE1/AE3, EMA positive in epithelial components. Vimentin positive in spindle elements.
Molecular genetics: MET exon 14 skipping mutations occur in ~20-30% of pleomorphic carcinomas - significantly higher than in adenocarcinoma, making this a targetable alteration in this rare subtype. - Fishman's Pulmonary Diseases

8. Adenosquamous Carcinoma

Defined as a carcinoma containing both SCC and adenocarcinoma components, each comprising >10% of the tumor. Incidence ~2-3%.
  • More common in smokers but occurs in nonsmokers
  • More common peripherally
  • Molecular data show both components share similar driver mutations, confirming a clonally identical tumor (not a "collision tumor")
  • Prognosis is worse than other NSCLC subtypes
  • Targeted therapy selection follows the guidelines for adenocarcinoma genetics

Comparison Table: Key Molecular Features (Robbins Table 11.6)

FeatureSCLCAdenocarcinomaSCC
3p deletions~90%~80%~80%
RB mutations~90%~20%~20%
p16/CDKN2A mutations~10%~30%~50%
TP53 mutations~90%~50%~80%
KRAS mutationsRare~30%Rare
EGFR mutationsAbsent~20% (nonsmokers, women)Rare
ALK fusionsAbsent4-6%Absent
NE markersPresentAbsentAbsent
Response to chemo/RTHigh (but invariably recurs)IncompleteIncomplete
Checkpoint inhibitor responseUnresponsiveResponsiveResponsive
Paraneoplastic hormonesACTH, ADH, GRP, calcitonin--PTHrP (hypercalcemia)

General Molecular Targets in Lung Carcinoma (Murray & Nadel's / Robbins)

The clinically relevant molecular targets as of the 2021 WHO era:
AlterationTumor TypeDrug Class
EGFR exon 19 del / L858RAdenocarcinomaTKI (erlotinib, gefitinib, osimertinib)
EGFR T790M (resistance)Adenocarcinoma3rd gen TKI (osimertinib)
ALK fusionAdenocarcinomaALK inhibitor (crizotinib, alectinib, lorlatinib)
ROS1 fusionAdenocarcinomaROS1 inhibitor (crizotinib, entrectinib)
BRAF V600EAdenocarcinomaBRAF+MEK inhibitor (dabrafenib+trametinib)
MET exon 14 skippingAdeno/Pleomorphic carcinomaMET inhibitor (capmatinib, tepotinib)
RET fusionAdenocarcinomaRET inhibitor (selpercatinib, pralsetinib)
NTRK fusionAnyTRK inhibitor (larotrectinib, entrectinib)
KRAS G12CAdenocarcinomaKRAS inhibitor (sotorasib, adagrasib)
PD-L1 high expressionNSCLC (all)Checkpoint inhibitor (pembrolizumab)
High TMBNSCLCCheckpoint inhibitor

Paraneoplastic Syndromes Summary

SyndromeTumor TypeMediator
SIADHSCLCADH
Ectopic Cushing'sSCLCACTH
Eaton-Lambert myasthenic syndromeSCLCAnti-VGCC antibodies
HypercalcemiaSCCPTHrP
Hypertrophic pulmonary osteoarthropathyAdenocarcinomaUnclear
Hypercoagulability (Trousseau)Adenocarcinoma/mucin-secretingMucin activating clotting
Peripheral neuropathy, encephalopathySCLCAnti-Hu (ANNA-1) antibodies

Key Clinical Points

  • Pancoast tumor: Apical tumor (any histology) invading brachial/cervical sympathetic plexus → Pancoast syndrome (Horner + C8/T1 pain + rib/vertebral destruction)
  • Superior vena cava syndrome: Tumor compression/infiltration of SVC
  • Virchow's node (left supraclavicular): Characteristic lymphatic metastasis
  • All lung cancer subtypes can metastasize to adrenal glands, liver, brain, and bone (osteolytic); adenocarcinoma has highest predilection for CNS metastases
  • Staging: TNM system universally applied; SCLC also uses limited vs. extensive stage clinical staging

Sources:
  • Robbins & Kumar Basic Pathology (10th ed.) - Chapter 11, Table 11.5 and 11.6
  • Fishman's Pulmonary Diseases and Disorders (6th ed.) - Chapter 111 (Histologic Classification of Lung Tumors)
  • Sabiston Textbook of Surgery (21st ed.) - Chapter 110, Pathology section
  • Harrison's Principles of Internal Medicine (22nd ed., 2025)
  • Murray & Nadel's Textbook of Respiratory Medicine - Clinically relevant molecular targets in lung carcinoma
This is a shared conversation. Sign in to Orris to start your own chat.